AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise gross proceeds of $12 million for corporate purposes, including clinical trial expenses and debt repayment [1][4]. Rights Offering Details - The subscription rights are non-transferable and can be exercised from February 11, 2026, to February 27, 2026, unless extended [2][5]. - The rights offering includes an over-subscription privilege allowing holders to purchase additional unsubscribed shares, subject to pro-rata allocation if demand exceeds supply [2]. - AIM's leadership, including CEO Thomas K. Equels, has indicated a non-binding intention to participate in the rights offering [3]. Financial Use of Proceeds - The net proceeds from the rights offering will be allocated for general corporate purposes, specifically for clinical trial and manufacturing expenses related to Phase 2/3 pancreatic cancer trials, as well as repaying existing debt [4]. Important Dates - Key dates for the rights offering include: - February 9, 2026: Ownership Day for stockholder record [8] - February 10, 2026: Record Date [8] - February 11, 2026: Subscription Period Begins [8] - February 27, 2026: Subscription Period Ends [8] Registration and Compliance - A registration statement has been filed with the SEC but is not yet effective, meaning securities cannot be sold until it becomes effective [9]. - The rights offering will be conducted only through a written prospectus [9]. Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with its lead product being Ampligen® [11].